Key facts
- Origin Endoscopy’s last known valuation is $8.0M (Jun 2025).
- It has raised $2.3M across 1 recorded rounds; the latest was Seed Round ($2.3M) in Sep 2024.
- Notable investors include Innosphere Ventures, Highpoint Ventures, Johns Hopkins Technology Ventures, Monarc Partners.
- Origin Endoscopy has filed 3 Form Ds with the SEC since 2024, most recently Jun 2025 ($2.3M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Origin Endoscopy
Funding rounds
1 roundsAbout Origin Endoscopy
Developer of endoscopy products designed to control gastrointestinal bleeding. The company specializes in diagnostics and reducing bleeding after a polyp procedure focusing on lower bowel and seal wounds, providing doctors with patient outcomes for procedures such as endoscopic mucosal or submucosal dissection.
- Sector
- Healthcare
- HQ
- Englewood, CO, United States
- Founded
- 2022
- Website
- originendoscopy.com/
- Ownership
- Privately Held (backing)
Origin Endoscopy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Origin Endoscopy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Origin Endoscopy in its N-PORT filings yet. We sweep new filings monthly.